AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02077257
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg/d compared to 10 mg/day
Trial: NCT03817424
Drug: VIB7734
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive VIB7734 via injection.
Trial: NCT03817424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to VIB7734 via injection.
Trial: NCT05008354
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine tablet 40mg once daily
Trial: NCT05008354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily
Trial: NCT01640808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 x Placebo capsules) orally, twice a day
Trial: NCT00325650
Drug: Placebo (for Rimonabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT00533377
Drug: CP-533, 536
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active study drug
Trial: NCT00533377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vehicle
Trial: NCT00533377
Drug: CP-533,536
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active study drug
Trial: NCT00183911
Drug: floxuridine, 5-Fluorouracil, leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02921997
Drug: AS03
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 oil-in-water emulsion adjuvant.
Trial: NCT02401191
Drug: FEX60/PE10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT00878631
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ccs of normal saline infused within 4 hours of the accident
Trial: NCT03545893
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
Trial: NCT00176618
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac 150 mg po BID
Trial: NCT02910011
Drug: Nanodox 1% (doxycycline monohydrate hydrogel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
Trial: NCT01577550
Drug: Placebo, i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. administration of placebo
Trial: NCT01577550
Drug: Placebo, s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single s.c. administration of placebo
Trial: NCT00796107
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R1507 was administered at a dose 16 mg/kg every 3 weeks.
Trial: NCT01988246
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection. No actual injection. No medication is used.
Trial: NCT01572727
Drug: BKM120 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
Trial: NCT01572727
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
Trial: NCT02166008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03071692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 matching placebo tablet
Trial: NCT03173040
Drug: NiuBangZi pill or NiuBangZi pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
Trial: NCT03651089
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of sterile saline
Trial: NCT00687648
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by mouth
Trial: NCT04022876
Drug: ALRN-6924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
Trial: NCT04022876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
Trial: NCT04022876
Drug: ALRN-6924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
Trial: NCT00687648
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by mouth
Trial: NCT00687648
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT05984953
Drug: statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of rosuvastatin daily for 8-12 weeks
Trial: NCT02363946
Drug: ARC-AAT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA interference-based, liver-targeted therapeutic
Trial: NCT04050826
Drug: Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT03119467
Drug: RP4010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses starting at 25 mg
Trial: NCT01302119
Drug: AN2690 Topical Solution, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Trial: NCT01302119
Drug: Solution Vehicle
RxNorm normalized name: Flavor Sweet Oral Solution Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Trial: NCT02466022
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus 0.1cc/kg Normal Saline over 10 min
Trial: NCT02466022
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal Fentanyl 10ug
Trial: NCT04207931
Drug: Topical steroid class I-II
RxNorm normalized name: Defend II Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied once daily - 18 month duration of the study
Trial: NCT03713632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300mg every 2 or every 4 weeks
Trial: NCT04207931
Drug: Doxycyline
RxNorm normalized name: Doxycycline 50 MG Oral Tablet [DOXYCYLINE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral antibiotic twice daily for 6 months
Trial: NCT03853512
Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)
RxNorm normalized name: Derma Gran Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product is applied to one side of the inguinal region.
Trial: NCT02888730
Drug: Tobramycin nebulized nasally
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition.
Trial: NCT02638896
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (0.4g/d) will be the background therapy.
Trial: NCT04468984
Drug: Best Available Therapy (BAT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet/Capsule; Oral or Solution for Subcutaneous Injection
Trial: NCT03697824
Drug: GSK3377794
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
Trial: NCT03697824
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Trial: NCT01780909
Drug: Paromomycin Sulfate Fasted State
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01780909
Drug: Paromomycin Sulfate Fed State
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01780909
Drug: Paromomycin Sulfate w/ loperamide HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01044420
Drug: mFOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
Trial: NCT02871401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
Trial: NCT01193816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02935699
Drug: Test Drug (JDP-205)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Trial: NCT02156492
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00374855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03264794
Drug: Gefitinib tablets (Yi Ruisha），First medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib tablets (Yi Ruisha），First medication,250mg；
Trial: NCT04080869
Drug: retinyl palmitate
RxNorm normalized name: Retinyl palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical retinyl palmitate loaded ethosomes
Trial: NCT04080869
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical tretinoin
Trial: NCT00002783
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04977882
Drug: Postoperative antibiotico-prophylaxis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
Trial: NCT01935817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01300546
Drug: Sumatriptan/Naproxen Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
Trial: NCT01300546
Drug: Naproxen Sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
Trial: NCT03511599
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matched to cycloserine tab
Trial: NCT02708771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 daily capsules of similar appearance and flavor without active ingredient
Trial: NCT04146376
Drug: VWF replacement therapy with Wilate
RxNorm normalized name: factor VIII / von Willebrand factor Injection [Wilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy
Trial: NCT02155361
Drug: Topical Citrullus colocynthis fruit oil (1%)
RxNorm normalized name: Citrullus colocynthis fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02152254
Drug: Standard-of-Care Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment regimen will be left to the discretion of the treating physician.
Trial: NCT03106948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
Trial: NCT03106948
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
Trial: NCT03106948
Drug: Cuprimine Oral Product
RxNorm normalized name: Cuprimine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
Trial: NCT02160587
Drug: 0.9% Physiological Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
Trial: NCT00990990
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BID for 14 days
Trial: NCT00990990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to match 100 mg BID for 14 days
Trial: NCT00990990
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg BID for 14 days
Trial: NCT00990990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to match 300 mg BID for 14 days
Trial: NCT00990990
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg BID for 14 days
Trial: NCT00990990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to match 600 mg BID for 14 days
Trial: NCT00990990
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg QD for 14 days
Trial: NCT00990990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to match 1200 mg QD for 14 days
Trial: NCT00990990
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Trial: NCT00990990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Trial: NCT00990990
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Trial: NCT00990990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Trial: NCT01019876
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01565707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
Trial: NCT03335956
Drug: CORT125281, 40mg, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125281 is supplied as capsules for oral dosing
Trial: NCT03335956
Drug: Placebo oral capsule, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered
Trial: NCT03335956
Drug: Placebo oral capsule, fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered
Trial: NCT03335956
Drug: CORT125281, 120mg, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125281 is supplied as capsules for oral dosing
Trial: NCT03335956
Drug: CORT125281, 360mg, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125281 is supplied as capsules for oral dosing
Trial: NCT03335956
Drug: CORT125281, 720mg, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125281 is supplied as capsules for oral dosing
Trial: NCT03335956
Drug: CORT125281, 360mg, fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125281 is supplied as capsules for oral dosing
Trial: NCT03335956
Drug: CORT125281, 360mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
Trial: NCT03335956
Drug: CORT125281, 360mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125281 is supplied as capsules for oral dosing once daily
Trial: NCT03335956
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal
Trial: NCT03335956
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily
Trial: NCT03335956
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily
Trial: NCT03591094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00868166
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
Trial: NCT00435604
Drug: Hylenex
RxNorm normalized name: Hylenex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01586143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00833638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally daily
Trial: NCT00364429
Drug: [123]I-CNS 1261
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT00793468
Drug: GSK598809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 once daily for 12 weeks
Trial: NCT00793468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 12 weeks
Trial: NCT03969719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01029223
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02130193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive danirixin matching placebo